Athersys, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04744L2051
USD
0.00
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Athersys, Inc. stock-summary
stock-summary
Athersys, Inc.
Pharmaceuticals & Biotechnology
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Company Coordinates stock-summary
Company Details
3201 Carnegie Ave , CLEVELAND OH : 44115-2634
stock-summary
Tel: 1 216 4319900
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 19 Schemes (2.58%)

Foreign Institutions

Held by 28 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Gil Van Bokkelen
Chairman of the Board, Chief Executive Officer
Dr. John Harrington
Executive Vice President, Chief Scientific Officer, Director
Dr. Hardy Kagimoto
Director
Ms. Katherine Kalin
Director
Mr. Baiju Shah
Director
Ms. Jane Wasman
Director
Dr. Ismail Kola
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - Sep 2023)
Net Profit:
-4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.48

stock-summary
Return on Equity

118.05%

stock-summary
Price to Book

0.00